Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
715 (USA) · Dr. Moreau
consented 2013-02-16
AEs
0
Serious
0
Dropout signal
–
Adverse events
No adverse events recorded.
Data queries
No data queries.